Evidence of physical ability to perform the requested privilege. Data from professional practice review by an organization(s) that currently privileges the applicant (if available). Peer and/or faculty recommendation. When renewing privileges, review of the practitionerâs performance within the hospital.
Janssen, however, also marketed Risperdal as a treatment for older people with agitation from dementia, which is not an FDA-approved use of the medication. In fact, it can be dangerous for older adults with dementia to take antipsychotics, including Risperdal, and Janssen had to pay a fine for misbranding the drug.
Mechanism Of Action. The mechanism of action of RISPERDALÂ®, in schizophrenia, is unknown. However, it has been proposed that the drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.he efficacy of RISPERDALÂ® in the treatment of acute manic or mixed episodes was established in two short-term (3-week) placebo-controlled trials in patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. These trials included patients with or without psychotic features.